CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
工程化干细胞用于癌症免疫治疗
英文原题：Engineering stem cells for cancer immunotherapy.
查看英文原题
Engineering stem cells for cancer immunotherapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
工程化干细胞为癌症免疫治疗提供了一种有吸引力的范式。经过工程化改造以稳定表达针对肿瘤相关抗原的各种嵌合抗原受体（CAR）或 T 细胞受体（TCR）的干细胞，在实体瘤和血液系统恶性肿瘤的治疗中展现出越来越大的前景。干细胞可长期植入以持续产生免疫细胞，并作为肿瘤特异性效应细胞的持久来源以维持缓解。此外，工程化干细胞提供了“现货型”细胞产品，免除了对个性化和患者特异性产品的需求，而后者正是当前自体细胞疗法面临的难题。本文中，我们总结了干细胞工程化癌症疗法的最新进展，并讨论了细胞工程化的实用性、影响、机遇和挑战，以期促进转化和临床研究。
展开英文摘要原文
Engineering stem cells presents an attractive paradigm for cancer immunotherapy. Stem cells engineered to stably express various chimeric antigen receptors (CARs) or T-cell receptors (TCRs) against tumor-associated antigens are showing increasing promise in the treatment of solid tumors and hematologic malignancies. Stem cells engraft for long-term immune cell generation and serve as a sustained source of tumor-specific effector cells to maintain remissions.
Furthermore, engineering stem cells provides 'off-the-shelf' cellular products, obviating the need for a personalized and patient-specific product that plagues current autologous cell therapies.
Herein, we summarize recent progress of stem cell-engineered cancer therapies, and discuss the utility, impact, opportunities, and challenges of cellular engineering that may facilitate the translational and clinical research.
论文信息
- 作者
- Li YR、Zhou Y、Kramer A、Yang L
- 第一作者单位
- Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.United States
- 通讯作者单位
- Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA. Electronic address: liliyang@ucla.edu.United States
- 文献类型
- 美国 NIH 资助研究 · 非美国政府资助研究 · 综述
- 期刊
- Trends in cancer2021 Dec
- 原文标识
- PubMed 34479851 · DOI 10.1016/j.trecan.2021.08.004